We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

PDS Biotechnology Corporation (PDSB) USD0.00033

Sell:$3.20 Buy:$3.29 Change: $0.01 (0.31%)
Market closed |  Prices as at close on 25 April 2024 | Switch to live prices |
Sell:$3.20
Buy:$3.29
Change: $0.01 (0.31%)
Market closed |  Prices as at close on 25 April 2024 | Switch to live prices |
Sell:$3.20
Buy:$3.29
Change: $0.01 (0.31%)
Market closed |  Prices as at close on 25 April 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

PDS Biotechnology Corporation is a clinical-stage immunotherapy company. The Company is developing a pipeline of targeted cancer immunotherapies based on its Versamune T cell-activator and Versamune in combination with its interleukin 12 (IL-12) fused antibody drug conjugate (ADC), PDS01ADC, a tumor targeting immunocytokine. PDS0101 is its lead Versamune based immunotherapy. PDS0101 combines Versamune with a mixture of short proteins (peptides) derived from the cancer-causing HPV16 viral protein. Versamune is a proprietary lipid nanoparticle and T cell activating platform. PDS0301 is an investigational tumor-targeting antibody conjugate of Interleukin 12 (IL-12) that enhances the proliferation, potency, infiltration, and longevity of T cells in the tumor microenvironment. Its Versamune immunotherapies and Versamune in combination with PDS01ADC, are utilized for treatments in oncology, and Infectimune is utilized for preventive vaccines against infectious agents.

Contact details

Address:
303A College Road East
PRINCETON
08540
United States
Telephone:
+ ()
Website:
https://www.pdsbiotech.com

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
PDSB
ISIN:
US70465T1079
Market cap:
$117.37 million
Shares in issue:
36.68 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Frank Bedu-Addo
    President, Chief Executive Officer, Director
  • Lars Boesgaard
    Chief Financial Officer
  • Spencer Brown
    Senior Vice President, General Counsel
  • Sanjay Zaveri
    Senior Vice President - Business Development
  • Gregory Conn
    Chief Scientific Officer
  • Kirk Shepard
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.